Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients

Table 6 Univariate and multivariate progression-free survival in colorectal cancer patients

Variables	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Gross pattern	1.96 (1.53-2.50)	< 0.001	1.54 (1.20-1.98)	0.001
(infiltrative/fungating)
Stage	4.59 (3.40-6.19)	< 0.001	4.11 (3.04-5.57)	< 0.001
(III, IV/I, II)
Differentiation	3.43 (2.12-5.54)	< 0.001	1.57 (0.92-2.70)	0.100
(undifferentiated/differentiated)
CDX2 expression	2.99 (2.02-4.43)	< 0.001	1.94 (1.22-3.07)	0.005
(loss/retained)
CIMP	1.84 (1.21-2.80)	0.004	1.03 (0.64-1.67)	0.892
(CIMP-high/CIMP-0, low)
Age (yr)	1.17 (0.91-1.49)	0.223
(≥ 65/< 65)
Sex	1.03 (0.81-1.33)	0.794
(female/male)
Tumor location	1.16 (0.89-1.53)	0.269
(proximal colon/distal colon, rectum)
Adjuvant chemotherapy	1.14 (0.88-1.49)	0.449
(treatment/no-treatment)
CK7 expression	0.88 (0.56-1.37)	0.571
(increased/no-expression)
CK20 expression	1.00 (0.70-1.45)	0.986
(decreased/retained)
MSI	0.81 (0.49-1.32)	0.395
(MSI-high/MSS, MSI-low)
KRAS mutation	0.98 (0.74-1.31)	0.914
(Mt/Wt)
BRAF mutation	1.17 (0.69-1.96)	0.567
(Mt/Wt)

CIMP: CpG island methylator phenotype; MSI: Microsatellite instability; MSS: Microsatellite stable; Mt: Mutant type; Wt: Wild type; CK: Cytokeratin.